Difference between revisions of "Part:BBa K4414024"

 
(6 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K4414024 short</partinfo>
 
<partinfo>BBa_K4414024 short</partinfo>
  
This composite part consists of an N-terminal tetR([[Part:BBa_K4414009]]) domain and a C-terminal NR3C1 LBD([[Part:BBa_K4414000]]) domain fused with a GGGSG linker. It is designed to sense glucocorticoids and activates the transcription of the reporter gene.
+
This composite part consists of an N-terminal tetR([[Part:BBa_K4414009]]) domain and a C-terminal GR LBD([[Part:BBa_K4414000]]) domain fused with a GGGSG linker. It is designed to sense glucocorticoids and activates the transcription of the reporter gene.
  
  
 
==Usage and Biology==
 
==Usage and Biology==
  
As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter ([[Part:BBa_K4016011]]) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The NR3C1 LBD domain on the C terminal is the ligand binding domain of the glucocorticoid receptor(GR). This LBD domain can translocate the fusion protein into the nucleus upon glucocorticoid stimulation. It also has a transactivating domain 2 (τ2) and an activation function domain 2 (AF2) which activates downstream gene expression.(Weikum et al., 2017)
+
As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter ([[Part:BBa_K4016011]]) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The GR LBD domain on the C terminal is the ligand binding domain of the glucocorticoid receptor(GR). This LBD domain can translocate the fusion protein into the nucleus upon glucocorticoid stimulation. It also has a transactivating domain 2 (τ2) and an activation function domain 2 (AF2) which activates downstream gene expression(Weikum et al., 2017).
  
 
<html>
 
<html>
Line 18: Line 18:
  
 
</html>
 
</html>
Figure1. Schematic figure of BBa_K4414024 and ([[Parts:BBa_K4414041]])
+
Figure1. Schematic figure of BBa_K4414024 and ([[Part:BBa_K4414041]])
  
<span class='h3bb'>Sequence and Features</span>
+
<!-- -->
 +
===Sequence and Features===
 
<partinfo>BBa_K4414024 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4414024 SequenceAndFeatures</partinfo>
  
Line 28: Line 29:
 
<partinfo>BBa_K4414024 parameters</partinfo>
 
<partinfo>BBa_K4414024 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
  
 
==Functional Test==
 
==Functional Test==
To test the ability of this part to respond to glucocorticoids, HEK-293T cells were co-transfected with plasmids encoding both BBa_K4414024 and TCE-SEAP([[Parts:BBa_K4414041]]).
+
To test the ability of this part to respond to glucocorticoids, HEK-293T cells were co-transfected with plasmids encoding both BBa_K4414024 and TCE-SEAP([[Part:BBa_K4414041]]).
 
===Method===
 
===Method===
 
<html>
 
<html>
Cells were treated with 10, 50, or 100 nM Glucocorticoids 6 h post-transfection. Cells without glucocorticoid treatment were used as control. Culture medium was collected at 24 h or 48 h post glucocorticoids treatment. SEAP activity was measured according to a published protocol. (Shao et al., 2021)
+
Cells were treated with 10, 50, or 100 nM Glucocorticoids 6 h post-transfection. Cells without glucocorticoid treatment were used as control. Culture medium was collected at 24 h or 48 h post glucocorticoids treatment. SEAP activity was measured according to a published protocol (Shao, Qiu, & Xie, 2021).
  
  
Line 43: Line 45:
  
 
</html>
 
</html>
Figure2.Schematic representation of the experimental process of validation for BBa_K4414024 and ([[BBa_K4414041]]).
+
Figure2.Schematic representation of the experimental process of validation for BBa_K4414024 and ([[Part:BBa_K4414041]]).
  
 
===Result===
 
===Result===
Line 62: Line 64:
  
 
==Reference==
 
==Reference==
1.Weikum ER, Knuesel MT, Ortlund EA, Yamamoto KR. Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol. 2017 Mar;18(3):159-174. doi: 10.1038/nrm.2016.152. Epub 2017 Jan 5. PMID: 28053348; PMCID: PMC6257982.
+
1.Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017). Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol, 18(3), 159-174. doi:10.1038/nrm.2016.152
 
+
2. Shao, J., Qiu, X., & Xie, M. (2021). Engineering Mammalian Cells to Control Glucose Homeostasis. Methods Mol Biol, 2312, 35-57. doi:10.1007/978-1-0716-1441-9_3
2.Shao J, Qiu X, Xie M. Engineering Mammalian Cells to Control Glucose Homeostasis. Methods Mol Biol. 2021;2312:35-57. doi: 10.1007/978-1-0716-1441-9_3. PMID: 34228283.
+

Latest revision as of 17:49, 11 October 2022


tetR-GGGSG-LBD

This composite part consists of an N-terminal tetR(Part:BBa_K4414009) domain and a C-terminal GR LBD(Part:BBa_K4414000) domain fused with a GGGSG linker. It is designed to sense glucocorticoids and activates the transcription of the reporter gene.


Usage and Biology

As a glucocorticoid sensor, this part is designed to enter the nucleus upon glucocorticoid stimulation and bind to the TCE promoter to activate downstream transcription. This part consists of a tetR DNA binding domain, which binds to the TCE promoter (Part:BBa_K4016011) consisting of seven direct 19-bp tet operator sequence (tetO) repeats. The GR LBD domain on the C terminal is the ligand binding domain of the glucocorticoid receptor(GR). This LBD domain can translocate the fusion protein into the nucleus upon glucocorticoid stimulation. It also has a transactivating domain 2 (τ2) and an activation function domain 2 (AF2) which activates downstream gene expression(Weikum et al., 2017).

Figure1. Schematic figure of BBa_K4414024 and (Part:BBa_K4414041)

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]



Functional Test

To test the ability of this part to respond to glucocorticoids, HEK-293T cells were co-transfected with plasmids encoding both BBa_K4414024 and TCE-SEAP(Part:BBa_K4414041).

Method

Cells were treated with 10, 50, or 100 nM Glucocorticoids 6 h post-transfection. Cells without glucocorticoid treatment were used as control. Culture medium was collected at 24 h or 48 h post glucocorticoids treatment. SEAP activity was measured according to a published protocol (Shao, Qiu, & Xie, 2021).

Figure2.Schematic representation of the experimental process of validation for BBa_K4414024 and (Part:BBa_K4414041).

Result

Results showed significantly increased SEAP expression in glucocorticoid-treated cells compared to the non-treated control (2-5 folds). A dose dependence was observed within 0-50 nM of glucocorticoid (Figure 3).

Figure3. Glucocorticoid-stimulated transcriptional activation of SEAP mediated by BBa_K4414024.

Reference

1.Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017). Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol, 18(3), 159-174. doi:10.1038/nrm.2016.152 2. Shao, J., Qiu, X., & Xie, M. (2021). Engineering Mammalian Cells to Control Glucose Homeostasis. Methods Mol Biol, 2312, 35-57. doi:10.1007/978-1-0716-1441-9_3